| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Obstetrics and Gynecology [A. A. A.] and Pathology [H. R. K.], Division of Gynecologic Oncology, Department of Obstetrics and Gynecology [R. S. W., G. C. R.], and Department of Biostatistics, Duke Comprehensive Cancer Center [R. K. D.], Duke University Medical Center, Durham, North Carolina 27710
The molecular biology underlying the metastatic process in ovarian carcinoma remains poorly understood. For other neoplasms, the induction of angiogenesis by malignant cells has been shown to play a pivotal role in the process of tumor proliferation and metastasis. The purpose of this study was to characterize the degree of angiogenesis in epithelial ovarian malignancies and to determine whether the degree of neovascularization has prognostic significance for survival.
Tissue sections obtained from 88 ovarian cancer patients were examined immunohistochemically for angiogenesis after staining with anti-human endothelial cell antibodies to von Willebrand factor and CD31. Light microscopy was performed, and individual microvessel counts were quantified at high power (x400). A chart review was completed, collating data regarding age, stage, grade, status of disease, and survival. Statistical exploratory methods were used to find potentially useful prognostic cutpoints for marker values of angiogenesis.
Of the total 88 patients, tissue microvessel counts from 85 were evaluated via antibodies to von Willebrand factor and 87 for CD31. Overall, median survival was 2.7 years in women with cancers containing high microvessel counts versus 7.9 years in those with low microvessel counts (P = 0.03). A low microvessel count was associated with better 5-year survival in both early stage (I and II) and advanced stage (III and IV) disease.
Our data suggest that the degree of neovascularization may have prognostic significance in epithelial ovarian carcinoma, especially for women with early-stage disease. In this group of women, the degree of angiogenesis may allow the selection of women at high risk for recurrence who may benefit from aggressive adjuvant therapy.
This article has been cited by other articles:
|
|
 |
|
  S. B. Kaye Bevacizumab for the Treatment of Epithelial Ovarian Cancer: Will This Be Its Finest Hour? J. Clin. Oncol., November 20, 2007; 25(33): 5150 - 5152. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., November 20, 2007; 25(33): 5165 - 5171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Cannistra, U. A. Matulonis, R. T. Penson, J. Hambleton, J. Dupont, H. Mackey, J. Douglas, R. A. Burger, D. Armstrong, R. Wenham, et al. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5180 - 5186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Burger Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2902 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hagemann, S. C. Robinson, R. G. Thompson, K. Charles, H. Kulbe, and F. R. Balkwill Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis Mol. Cancer Ther., July 1, 2007; 6(7): 1993 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Goodheart, J. M. Ritchie, S. L. Rose, J. P. Fruehauf, B. R. De Young, and R. E. Buller The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3733 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Pietras and O. K. Weinberg Antiangiogenic Steroids in Human Cancer Therapy Evid. Based Complement. Altern. Med., March 1, 2005; 2(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Chan, V. Loizzi, A. Magistris, F. Lin, J. Rutgers, K. Osann, P. J. DiSaia, and M. L. Berman Differences in Prognostic Molecular Markers between Women Over and Under 45 Years of Age with Advanced Ovarian Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8538 - 8543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J. M. Cherrington, E. Scanziani, M. I. Nicoletti, et al. The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically Clin. Cancer Res., August 1, 2003; 9(9): 3476 - 3485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rosano, F. Spinella, D. Salani, V. Di Castro, A. Venuti, M. R. Nicotra, P. G. Natali, and A. Bagnato Therapeutic Targeting of the Endothelin A Receptor in Human Ovarian Carcinoma Cancer Res., May 15, 2003; 63(10): 2447 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. M. Dings, Y. Yokoyama, S. Ramakrishnan, A. W. Griffioen, and K. H. Mayo The Designed Angiostatic Peptide Anginex Synergistically Improves Chemotherapy and Antiangiogenesis Therapy with Angiostatin Cancer Res., January 15, 2003; 63(2): 382 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E S Bamberger and C W Perrett Angiogenesis in epithelian ovarian cancer Mol. Pathol., December 1, 2002; 55(6): 348 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Sood, M. S. Fletcher, and M. J. C. Hendrix The Embryonic-Like Properties of Aggressive Human Tumor Cells Reproductive Sciences, January 1, 2002; 9(1): 2 - 9. [Abstract] [PDF]
|
|
|
|
 |
|
 A. K. Sood, E. A. Seftor, M. S. Fletcher, L. M. G. Gardner, P. M. Heidger, R. E. Buller, R. E. B. Seftor, and M. J. C. Hendrix Molecular Determinants of Ovarian Cancer Plasticity Am. J. Pathol., April 1, 2001; 158(4): 1279 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Andrews, A. Ribas, L. H. Butterfield, C. M. Vollmer, F. C. Eilber, V. B. Dissette, S. D. Nelson, P. Shintaku, S. Mekhoubad, T. Nakayama, et al. Adenovirus-Interleukin-12-mediated Tumor Regression in a Murine Hepatocellular Carcinoma Model Is Not Dependent on CD1-restricted Natural Killer T Cells Cancer Res., November 1, 2000; 60(22): 6457 - 6464. [Abstract] [Full Text]
|
|
|
|
|
|
D. Salani, V. Di Castro, M. R. Nicotra, L. Rosano, R. Tecce, A. Venuti, P. G. Natali, and A. Bagnato Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma Am. J. Pathol., November 1, 2000; 157(5): 1537 - 1547. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
